Is Acemini an ATP-competing TKI? Detailed explanation of the mechanism of action

Asciminib is a novel kinase inhibitor used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML), especially those who have failed to respond to conventional treatments. It is an ABL1 kinase inhibitor, but is different from traditional tyrosine kinase inhibitors (TKIs). Traditional TKIs, such as Imatinib, Dasatinib and Nilotinib, bind to ABL1 kinase through ATP competition, inhibiting its activity, thereby preventing tumor cell proliferation. However, acemini's mechanism of action is unique.

Aximini does not simply compete withATP binding, but binds to the active site of ABL1 kinase through a new mechanism. Specifically, aximini is a "site-specific" ABL1 inhibitor that inhibits the activity of ABL1 kinase by targeting specific sites of ABL1 kinase - that is, structural regions that are different from traditional TKIs. This mechanism allows Asiminib to bypass certain resistance mutations of classical TKIs, especially the T315I mutation, which is usually insurmountable by traditional TKIs.

Aximini’s unique mechanism of action makes it a new treatment option for some patients with strong immune resistancePh+ CML. It blocks the function of ABL1 by binding to the "protein-protein interaction site" of ABL1 kinase rather than the ATP-binding site, thereby inhibiting cancer cells. Studies have shown that aximini can significantly improve clinical effects and provide a higher treatment success rate in some patients who are refractory to traditional TKI treatment.

Different from traditionalATP-competitive TKIs, Asiminib’s non-ATP-competitive mechanism gives it advantages in specific situations, especially in patients with drug-resistant mutations, so it is considered an innovative treatment strategy for chronic myelogenous leukemia.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib